XML 77 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Revenues $ 2,392 $ 709
Less:    
Cost of revenues 508 488
R&D costs 8,137 9,066
G&A costs 10,269 12,184
Net loss (15,973) (21,413)
Reportable Segment [Member]    
Segment Reporting Information [Line Items]    
Revenues [1] 2,392 709
Less:    
Cost of revenues 508 488
R&D costs [2] 2,799 5,704
G&A costs [3] 5,646 6,869
Personnel costs [4] 9,002 7,731
Other segment items [5] 410 1,330
Net loss $ (15,973) $ (21,413)
[1] Includes Contract Manufacturing and Clinical Trial revenue
[2] Includes Clinical Development, Research & Discovery, CMC
[3] Includes Executive, Finance, Legal, Business Operations
[4] Includes compensation, benefits and equity-based compensation
[5] Includes depreciation and amortization, (interest income) and other specific charges